bevacizumab

By Targets:	Akt (1) Amyloid-β (3) Anaplastic lymphoma kinase (ALK) (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) Bacterial (2) CD28 (1) Drug Derivative (1) Epigenetic Reader Domain (3) HIV (2) Phosphodiesterase (PDE) (3) Reference Standards (1) Transmembrane Glycoprotein (1) VEGFR (4)
By Research Areas:	Cancer (11) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (1) Neurological Disease (4)
Click Chemistry:	Tetrazine (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9906

*Bevacizumab* Maximum Cited Publications 51 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

HY-16900

Rolipram 15+ Cited Publications (R,S)-Rolipram; (±)-Rolipram; ZK 62711	Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Infection Neurological Disease Cancer
Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

HY-P9906A

Bevacizumab (Anti-VEGFA) Maximum Cited Publications 51 Publications Verification	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .

HY-P9986

Tiragolumab MTIG-7192A; RG-6058	CD28	Cancer
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .

HY-P99353

Ascrinvacumab 2 Publications Verification Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962; GT-90001C	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

HY-16900R

Rolipram (Standard) (R,S)-Rolipram (Standard); (±)-Rolipram (Standard); ZK 62711 (Standard)	Reference Standards Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Neurological Disease Cancer
Rolipram (Standard) is the analytical standard of Rolipram (HY-16900). This product is intended for research and analytical applications. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

HY-185208

Bevacizumab vedotin	Antibody-Drug Conjugates (ADCs) VEGFR Apoptosis	Cancer
Bevacizumab vedotin is an antibody-drug conjugate (ADC). Bevacizumab vedotin blocks the VEGF/VEGFR pathway to exert anti-angiogenic effects. Bevacizumab vedotin exhibits anti-proliferative effects on cancer cells, promotes cancer cell apoptosis (Apoptosis), induces cancer cell cycle arrest, and possesses anti-migratory activity against breast cancer cells. Bevacizumab vedotin can be used in research related to glioma, hepatocellular carcinoma, and breast cancer .

HY-132003

Wortmannin-Rapamycin Conjugate 1	Akt	Cancer
Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research .

HY-W422109

4-(6-Methyl-1,2,4,5-tetrazin-3-yl)benzoic acid	Drug Derivative	Others
4-(6-Methyl-1,2,4,5-tetrazin-3-yl) benzoic acid is an asymmetric tetrazine derivative and a bioorthogonal reaction partner. 4-(6-Methyl-1,2,4,5-tetrazin-3-yl) benzoic acid can be conjugated with Bevacizumab (HY-P9906) via EDC/NHS activation while retaining the VEGF-binding affinity of the antibody, thus constructing a targeting agent for pretargeted immuno-PET/NIRF imaging .

HY-P992082

Anti-Human/Rat VEGF Antibody (A.4.6.1)	VEGFR	Cancer
Anti-Human/Rat VEGF Antibody (A.4.6.1) is an antibody targeting human and rat vascular endothelial growth factor (VEGF) that potently inhibits tumor growth in various animal models. Anti-Human/Rat VEGF Antibody (A.4.6.1) is the parent antibody of Bevacizumab (HY-P9906), and it exhibits high affinity and high selectivity for binding to human VEGF . The isotype control for Anti-Human/Rat VEGF Antibody (A.4.6.1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-16900G

Rolipram	Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Neurological Disease Inflammation/Immunology Cancer
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

HY-P99658A

Imaprelimab (powder)	Transmembrane Glycoprotein	Cardiovascular Disease Neurological Disease Cancer
Imaprelimab (powder) is a humanized IgG1κ anti-CD146 antibody. Imaprelimab (powder) exerts anti-angiogenic effects on brain metastasis of lung cancer in animal models. Imaprelimab (powder) can be used in studies related to brain metastasis of non-small cell lung cancer .

Cat. No.	Product Name	Type

HY-16900G

Rolipram	Fluorescent Dyes
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Rolipram

Fluorescent Dyes

Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Cat. No.	Product Name	Type

HY-16900G

Rolipram	Biochemical Assay Reagents
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Rolipram

Biochemical Assay Reagents

Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9906

*Bevacizumab* Maximum Cited Publications 51 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

HY-P9906A

Bevacizumab (Anti-VEGFA) Maximum Cited Publications 51 Publications Verification	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .

HY-P9986

Tiragolumab MTIG-7192A; RG-6058	CD28	Cancer
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .

HY-P99353

Ascrinvacumab 2 Publications Verification Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962; GT-90001C	Anaplastic lymphoma kinase (ALK)	Cancer
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a K_d value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .

HY-P992082

Anti-Human/Rat VEGF Antibody (A.4.6.1)	VEGFR	Cancer
Anti-Human/Rat VEGF Antibody (A.4.6.1) is an antibody targeting human and rat vascular endothelial growth factor (VEGF) that potently inhibits tumor growth in various animal models. Anti-Human/Rat VEGF Antibody (A.4.6.1) is the parent antibody of Bevacizumab (HY-P9906), and it exhibits high affinity and high selectivity for binding to human VEGF . The isotype control for Anti-Human/Rat VEGF Antibody (A.4.6.1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P99658A

Imaprelimab (powder)	Transmembrane Glycoprotein	Cardiovascular Disease Neurological Disease Cancer
Imaprelimab (powder) is a humanized IgG1κ anti-CD146 antibody. Imaprelimab (powder) exerts anti-angiogenic effects on brain metastasis of lung cancer in animal models. Imaprelimab (powder) can be used in studies related to brain metastasis of non-small cell lung cancer .

Cat. No.	Product Name		Classification

HY-W422109

4-(6-Methyl-1,2,4,5-tetrazin-3-yl)benzoic acid		Tetrazine
4-(6-Methyl-1,2,4,5-tetrazin-3-yl) benzoic acid is an asymmetric tetrazine derivative and a bioorthogonal reaction partner. 4-(6-Methyl-1,2,4,5-tetrazin-3-yl) benzoic acid can be conjugated with Bevacizumab (HY-P9906) via EDC/NHS activation while retaining the VEGF-binding affinity of the antibody, thus constructing a targeting agent for pretargeted immuno-PET/NIRF imaging .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16900G

Rolipram	Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Neurological Disease Inflammation/Immunology Cancer
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Inhibitory Antibodies

Click Chemistry

GMP Molecules

Name
Email *

	Sorry, but the email address you supplied was invalid.